NCT07199933View on ClinicalTrials.gov

Diacerein in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease

NANot yet recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
MAFLD
Interventions
DRUG

Diacerein 50 mg Capsule

Drug:Diacerein 50 mg Capsule. Weeks 1-4: 50 mg/day; Weeks 5-24: 100 mg/day.

DRUG

Placebo 50 mg

Drug:Placebo 50 mg Capsule. Weeks 1-4: 50 mg/day; Weeks 5-24: 100 mg/day.

All Listed Sponsors
lead

Hongyan Wu

OTHER

NCT07199933 - Diacerein in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease | Biotech Hunter | Biotech Hunter